Text Size
A A A
Skip Navigation

Home > RePORTER > Project Information

Project InformationProject Information Help

Project Number: 5R01CA088164-11 Contact PI / Project Leader: WITTE, JOHN S
Title: GENETIC EPIDEMIOLOGY OF PROSTATE CANCER AGGRESSIVENESS Awardee Organization: UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
Description
Abstract Text:
DESCRIPTION (provided by applicant): There is growing evidence that genes involved with innate immunity and inflammation may impact the risk of prostate cancer, as well as progression of the disease. During the initial funding period of this project we have successfully undertaken a number of complementary studies to investigate some of these candidate genes. Our preliminary results suggest that prostate cancer may be affected by variants in genes involved in the innate immune response and inflammation pathway (i.e., in RNASEL, OAS1, TNF-a, and LTA). We propose building on these findings by comprehensively evaluating the impact of candidate genes involved in this pathway on prostate cancer development and progression. Specifically, we first aim to evaluate the association between prostate cancer and single nucleotide polymorphisms and haplotypes in the following 23 candidate genes: Macrophage Scavenger Receptor 1, Toll-like Receptors 1, 2, 4, 5, 6, and 10, Ribonuclease L.,2',5'Oligoadenylate Sythetase 1 and 2, Interleukin 8, 1 Beta, and 1RN, Macrophage Migration Inhibitory Factor, Tumor Necrosis Factor Alpha, Lymphotoxin Alpha, Macrophage-lnhibitory-Cytokine-1, Cyclooxygenase-2, and five genes in the Nuclear Factor kappa- Beta Pathway. This study will use an existing population recruited during the initial funding period of this grant (N=1,454; 727 cases, 727 matched controls). Cases are men diagnosed with more clinically relevant disease (i.e., Gleason score >. 7, tumor-node-metastasis (TNM) stage > T2c, or prostate-specific antigen (PSA) >10), making this population ideally suited for studying both risk of prostate cancer and disease progression. Therefore, our second aim-is to collect prospective information on the course of the case's disease (e.g., post-treatment PSA levels), and then evaluate the relationship between these candidate genes and prostate cancer progression. Studying the same genes in these two aims will allow us to distinguish whether they are involved in prostate cancer risk and/or progression. Our final aim is to synthesize information on the candidate genes studied here by investigating their joint and interactive effects on prostate cancer development and progression with a novel hierarchical model. Determining the impact of candidate genes involved with the innate immunity and inflammation pathway on prostate cancer development and progression may have a significant impact on the public's health. In particular, the knowledge from this study may give important insights into the underlying mechanism of disease, provide a valuable screening tool for non-diseased men, and help guide treatment plans among men diagnosed with prostate cancer.
NIH Spending Category:
Aging; Cancer; Clinical Research; Genetic Testing; Genetics; Prostate Cancer; Urologic Diseases
Project Terms:
Address; advanced disease; Affect; Aftercare; Age; cancer risk; Candidate Disease Gene; chemokine; clinically relevant; cyclooxygenase 2; cytokine; Development; Diagnosis; Disease; Disease Progression; Ethnicity aspects; Evaluation; extracellular; Frequencies (time pattern); Funding; Genes; Genetic; genetic epidemiology; Gleason Grade for Prostate Cancer; Goals; Grant; Haplotypes; I Kappa B-Alpha; IL8 gene; Immune response; Inflammation; Inflammatory; insight; Interleukin-8; Joints; Knowledge; macrophage; macrophage scavenger receptors; Malignant neoplasm of prostate; member; men; Migration Inhibitory Factor; Modeling; Natural Immunity; Neoplasm Metastasis; Newly Diagnosed; NF-kappa B; novel; oligoadenylate; p65; Pathway interactions; Pattern Recognition; phenylpyruvate tautomerase; Phosphotransferases; Population; Population Study; Principal Investigator; programs; prospective; Prostate-Specific Antigen; Prostatic Diseases; public health medicine (field); receptor; Recruitment Activity; Reporting; Ribonucleases; Risk; Role; Screening procedure; Single Nucleotide Polymorphism; Site; Staging; TLR2 gene; TNF gene; TNFRSF5 gene; Toll-Like Receptor 1; Toll-like receptors; tool; treatment planning; tumor; Tumor Necrosis Factor-alpha; Tumor Necrosis Factor-Beta; tumor progression; Variant; Variation (Genetics); Viral



The RePORTER database is available to all public users at http://exporter.nih.gov/. As the data are available for bulk download, the RePORTER system reserves the right to block IP addresses that fail to adhere to instructions in the system’s robots.txt files or submit requests at a rate that negatively impacts service delivery to other users. RePORTER reserves the right to terminate any automated query to the RePORTER application that negatively affects service delivery to other users.

Page Last Updated on March 18, 2013
This site is best viewed with Internet Explorer (7.0 or higher) or Mozilla Firefox (3.0).

NIH...Turning Discovery Into Health®
RePORTER2